Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection

Hepatitis Monthly

Volumn 12, Issue 6, 2012, Pages 411-414

  Aghemo, Alessio ^a   Bhoori, Sherrie ^b   De Nicola, Stella ^a   Mazzaferro, Vincenzo ^b   Co Lombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Hepacivirus; Liver Transplantation; Silybin

Indexed keywords

EID: 85090704725     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.6135     Document Type: Article

References (17)

1. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000;32(4 Pt 1):852-8.
2. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999;29(1):250-6.
3. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8(3):679-87.
4. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immu-nosuppressive agents--a potentially lethal cocktail. Hepatology. 2011;54(1):3-5.
5. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacroli-mus. Hepatology. 2011;54(1):20-7.
6. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infec-tion: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-44.
7. Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, Ferenci P. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J Hep-atol. 2011;54(3):591-2; author reply 2-3.
8. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol. 2010;52(6):951-2.
9. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/riba-virin therapy. Gastroenterology. 2008;135(5):1561-7.
10. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long‐Term Treatment Against Cirrhosis (HALT‐C) Trial. Hepatology. 2008;47(2):605-12.
11. Freedman N, Curto T, Morishima C, Seeff L, Goodman Z, Wright E, et al. Silymarin use and liver disease progression in the Hepatitis C Antiviral Long‐Term Treatment against Cirrhosis trial. Aliment Pharmacol Therapeutics. 2011;33(1):127-37.
12. Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterol-ogy. 2010;138(2):671-81, 81 e1-2.
13. Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS. Understanding silibinin’s modes of action against HCV using viral kinetic mod-eling. J Hepatol. 2012;56(5):1019-24.
14. Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, et al. Silibinin and related compounds are direct inhibi-tors of hepatitis C virus RNA-dependent RNA polymerase. Gastro-enterology. 2010;138(3):1112-22.
15. Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pecheur EI, et al. Differential in vitro effects of intravenous versus oral for- mulations of silibinin on the HCV life cycle and inflammation. PLoS One. 2011;6(1):e16464.
16. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012;56 (Suppl 1):S88-100.
17. May MM, Lorengel H, Kreuter J, Zimmermann H, Ruebsamen-Schaeff H, Urban A. RNA-dependent RNA polymerases from different hepatitis C virus genotypes reveal distinct biochemi-cal properties and drug susceptibilities. Biochim Biophys Acta. 2011;1814(10):1325-32.